# Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers

> **NCT06508645** · PHASE1 · COMPLETED · sponsor: **Daewoong Pharmaceutical Co. LTD.** · enrollment: 33 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** DWP14012 injection

## Key facts

- **NCT ID:** NCT06508645
- **Lead sponsor:** Daewoong Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-01-10
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-04-06
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508645, "Study to Evaluate the Safety/Tolerability, PK and PD After Intravenous DWJ1521 Administration in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06508645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*